The increasing incidence of Candida infections fueled by novel host factors and the rising prevalence of drug-resistant Candida isolates are growing global concerns. Outbreaks of C. auris and fluconazole-resistant C. parapsilosis are reported globally, posing a major threat to immunocompromised and critically ill patients. The rising resistance to azoles and echinocandins among C. glabrata presents additional challenges. In May 2025, the European Confederation